<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041338</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-026</org_study_id>
    <nct_id>NCT02041338</nct_id>
  </id_info>
  <brief_title>Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer</brief_title>
  <official_title>Phase 2 Randomized Study of Different Neoadjuvant Regimens in Subtypes of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no standard neodjuvant regimens adapted according to the different subtypes of&#xD;
      breast cancer. This is a phase 2, randomized study to evaluate several regimens in different&#xD;
      subtypes of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is a heterogenous disease with at least 4 intrinsic subtypes including Luminal&#xD;
      A, Luminal B, HER2 enriched, Basal-like and normal breast like. Different subtypes have&#xD;
      different prognosis and treatment sensitivity. Thus, it would be more suitable to administer&#xD;
      different chemo-regimen in different subtypes. This is especially true in neoadjuvant&#xD;
      chemotherapy setting where no standard regimen has ever been established. Therefore, we&#xD;
      designed this phase 2 randomized clinical trial to explore potential effective regimens in&#xD;
      variable subtypes of breast cancer in neoadjuvant treatment. Patients were first classified&#xD;
      into Luminal type, Her2 positive type and triple-negative type by immunohistochemistry exam&#xD;
      of ER/PR/HER2 in core needle biopsy and then randomized to received either dose dense&#xD;
      paclitaxel in Luminal type or dose dense paclitaxel plus carboplatin with or without&#xD;
      trastuzumab in HER2 positive type or dose dense paclitaxel plus carboplatin in&#xD;
      triple-negative type.The control groups in each subtype all receive paclitaxel plus&#xD;
      epirubicin every 3 weeks. The duration of treatment is 4-6 cycles. Primary endpoint is the&#xD;
      pathological CR rate in each subtypes. Secondary endpoints include disease free survival,&#xD;
      objective response rate, safety. Tissue samples and blood samples will be collected at&#xD;
      baseline and during treatment. There will be exploratory biomarkers analyses to identify&#xD;
      predictive markers for efficacy in every subtypes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response(pCR) rate of breast and axilla after surgery</measure>
    <time_frame>3 years</time_frame>
    <description>pathological complete response(pCR) of breast and axilla after surgery means after operation, no invasive component can be found in both breast and axillary lymph nodes. The pCR rate is calculated by number of patients having pCR after sugery divided by number of patients receiving neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3years and 5years after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years and 5years after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>during screening and treatment, withing 21 days after day 1 of last cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Luminal subtype test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luminal subtype control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 positive subtype test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 positive subtype control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple negative subtype test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple negative subypte control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and carboplatin</intervention_name>
    <arm_group_label>Her2 positive subtype test</arm_group_label>
    <arm_group_label>Triple negative subtype test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Luminal subtype test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin and Paclitaxel</intervention_name>
    <arm_group_label>Her2 positive subtype control</arm_group_label>
    <arm_group_label>Luminal subtype control</arm_group_label>
    <arm_group_label>Triple negative subypte control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage IIa-IIIc breast cancer patients plan to receive neoadjuvant chemotherapy&#xD;
&#xD;
          -  Patients have enough tissue sample to do IHC test for subtype classification&#xD;
&#xD;
          -  Patients have at least one measurable lesion according to RECIST1.1&#xD;
&#xD;
          -  KPS≥80&#xD;
&#xD;
          -  No prior treatment for breast cancer&#xD;
&#xD;
          -  Adequate bone marrow (neutrophil count ≥1500 ml and platelet count ≥100,000 ml), renal&#xD;
             (serum creatinine &lt;1.5 times the upper limit of normal [ULN] or a creatinine clearance&#xD;
             of ≥60 ml/minute), hepatic (total bilirubin ≤1.5 ULN; alanine aminotransferase,&#xD;
             aspartate aminotransferase, and alkaline phosphatase ≤2.5 ULN), and cardiac function&#xD;
             (assessed by electrocardiogram or thoracic radiography) were required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fertile women were excluded if pregnant or lactating or if they were not using&#xD;
             adequate contraception.&#xD;
&#xD;
          -  Previous chemotherapy for breast cancer.&#xD;
&#xD;
          -  history of other serious illness (e.g. congestive heart failure, angina pectoris,&#xD;
             uncontrolled hypertension or arrhythmia, clinically significant neurologic or&#xD;
             psychiatric disorders, uncontrolled serious infection, AIDS), had an organ allograft,&#xD;
             severe gastrointestinal disorder, or other neoplasias (except for in situ cervical&#xD;
             cancer, non-melanoma skin cancer, or previous diagnosis of cancer with no evidence of&#xD;
             disease for &gt;10 years).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Fan, MD</last_name>
    <phone>861087788114</phone>
    <email>fanyingfy@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Fan, MD</last_name>
      <phone>861087788114</phone>
      <email>fanyingfy@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Xiang Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pin Zhang, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>MD, professor and Director of Department of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

